<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487629</url>
  </required_header>
  <id_info>
    <org_study_id>13368/2010</org_study_id>
    <nct_id>NCT01487629</nct_id>
  </id_info>
  <brief_title>Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema</brief_title>
  <acronym>IBERA-DME</acronym>
  <official_title>Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the morphological and visual acuity outcomes
      associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for
      treatment of diabetic macular edema.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central subfield macular thickness (CSFT) change</measure>
    <time_frame>Monthly from baseline to Week 48</time_frame>
    <description>Central subfield macular thickness (CSFT) measured with spectral-domain optical coherence tomography (OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity change</measure>
    <time_frame>Monthly from baseline to week 48</time_frame>
    <description>Best-corrected visual acuity using ETDRS charts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of macular edema with intravitreal Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of macular edema with intravitreal Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab, 1.5 mg, intravitreal, throughout the study</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab, 0.5 mg, intravitreal, throughout the study</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Center-involving Diabetic macular edema unresponsive to LASER therapy performed at
             least 3 moths prior to inclusion;

          -  Best corrected visual acuity equal or worse than 20/40 and better than 20/800;

          -  Central subfield macular thickness greater than 300 µm

        Exclusion Criteria:

          -  Aphakia

          -  High-risk proliferative diabetic retinopathy

          -  Previous treatment for DME in the past three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Jorge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Almeida, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital das Clinicas - Faculdade de Medicina de Ribeirão Preto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>December 9, 2011</last_update_submitted>
  <last_update_submitted_qc>December 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Rodrigo Jorge</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Macular Edema</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

